Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Ord Shs (OP:TKPHF)

31.59 UNCHANGED

Streaming Delayed Price Updated: 12:33 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ord Shs

< Previous 1 2 Next >

Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection ↗

November 24, 2021

The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after...

Via Benzinga

Takeda, Shattuck Labs Terminate Immuno-Oncology Pact ↗

November 09, 2021

Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154...

Via Benzinga

Takeda's 1H Sales Increase 13%, Reaffirms FY21 Outlook, Announces Share Buyback ↗

October 28, 2021

Takeda Pharmaceutical Company Limited (NYSE: TAK) reported 1H FY21 sales of ¥1,794.4 billion, +12.8%. Underlying core revenue increased +6.8% Y/Y, driven by 14...

Via Benzinga

Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs ↗

October 19, 2021

Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue...

Via Benzinga

Calithera Buys Two Oncology Candidates From Takeda For $45M ↗

October 19, 2021

Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK)....

Via Benzinga

Takeda Discontinues Two Mid-Stage Narcolepsy Trials ↗

October 06, 2021

Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin...

Via Benzinga

Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines ↗

October 01, 2021

Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA...

Via Benzinga

Takeda In-Licenses Hunter Syndrome Candidate ↗

September 30, 2021

Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to...

Via Benzinga

Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug ↗

September 24, 2021

In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in...

Via Benzinga

Mirum, Takeda Ink Maralixibat Licensing Pact In Japan ↗

September 21, 2021

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...

Via Benzinga

Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study ↗

September 02, 2021

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did...

Via Benzinga

UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma ↗

August 30, 2021

New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ)...

Via Benzinga

Moderna Withdraws Additional COVID-19 Shots In Japan: What You Need To Know ↗

August 30, 2021

After receiving reports on more contaminated vials and two deaths, Japan has suspended another million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19...

Via Benzinga

Topics Death

Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer ↗

August 26, 2021

Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received...

Via Benzinga

Takeda's Narcolepsy Candidate Gets FDA Breakthrough Therapy Tag ↗

July 28, 2021

The FDA has granted Breakthrough Therapy Designation to Takeda Pharmaceutical Company Limited's (NYSE: TAK) TAK-994 for excessive daytime sleepiness (EDS...

Via Benzinga

Japan To Buy Additional 50M Doses Of Moderna COVID-19 Vaccine ↗

July 20, 2021

Moderna Inc (NASDAQ: MRNA) has announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) will...

Via Benzinga

Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior Infection ↗

May 24, 2021

Takeda Pharmaceutical Co Ltd (NYSE: TAK) unveiled long-term data for its dengue vaccine candidate (TAK-003), showing the shot’s efficacy waned over time but...

Via Benzinga

Takeda's Maribavir US Application For Post-Transplant CMV Infection Under Review ↗

May 21, 2021

The FDA has accepted for review Takeda Pharmaceutical Co Ltd's (NYSE TAK) marketing application for maribavir for cytomegalovirus (CMV) Infection. The...

Via Benzinga

Moderna's COVID-19 Vaccine Scores Emergency Use Nod In Japan ↗

May 21, 2021

Moderna Inc (NASDAQ: MRNA) has received emergency use approval for its mRNA COVID-19 vaccine in Japan. Takeda Pharmaceutical Co Ltd (NYSE: TAK),...

Via Benzinga

Takeda FY20 Profit Surges, Revenue Drops; Guides For Weak FY21 Profit ↗

May 11, 2021

Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported an FY20 net profit of ¥376 billion, a 750% Y/Y increase, reflecting gains on non-core asset sales and...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.